Acumen price target lowered to $14 from $15 at UBS

UBS lowered the firm’s price target on Acumen Pharmaceuticals to $14 from $15 and keeps a Buy rating on the shares. The analyst updated the company’s model to include a reevaluation of the launch trajectory and probability of success for sabirnetug. Importantly, Acumen has sufficient cash to fund operations through the Phase 2 readout in early 2027, the analyst tells investors in a research note. The firm believes Acumen is now in a period of execution and sees an attractive buying opportunity at current valuation levels despite a “light catalyst path” in the near term.